Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays

被引：1

作者：

Hyams, David M. ^{[1
]}

Bareket-Samish, Avital ^{[2
]}

Rocha, Juan Enrique Bargallo ^{[3
,4
]}

Diaz-Botero, Sebastian ^{[5
]}

Franco, Sandra ^{[6
]}

Gagliato, Debora ^{[7
]}

Gomez, Henry L. ^{[8
]}

Korbenfeld, Ernesto ^{[9
]}

Krygier, Gabriel ^{[10
]}

Mattar, Andre ^{[11
]}

De Pierro, Anibal Nunez ^{[12
]}

Borrego, Manuel Ruiz ^{[13
]}

Villarreal, Cynthia ^{[14
]}

机构：

[1] Eisenhower Med Ctr, Desert Surg Oncol, Suite K-207,39000 Bob Hope Dr, Rancho Mirage, CA 92270 USA

[2] BioInsight Ltd, Binyamina, Israel

[3] Inst Nacl Cancerol Mexico, Breast Canc Dept, Mexico City, Mexico

[4] Ctr Med ABC, Mexico City, Mexico

[5] Clin Univ Navarra, Breast Surg Oncol Unit, Canc Ctr, Madrid, Spain

[6] CTIC, Ctr Tratamiento & Invest Canc, Bogota, Colombia

[7] Beneficencia Portuguesa Sao Paulo, Dept Clin Oncol, Sao Paulo, Brazil

[8] Univ Peruana Cayetano Heredia, Univ Ricardo Palma, OncoSalud, Clin Delgado,AUNA, Lima, Peru

[9] Hosp Britan Buenos Aires, Dept Oncol, Buenos Aires, Argentina

[10] Univ Hosp Clin, Dept Oncol, Montevideo, Uruguay

[11] Hosp Mulher, Mastol Ctr, Ctr Referencia Saude Mulher, Sao Paulo, Brazil

[12] Hosp JA Fernandez, Dept Surg, Unit Mastol, Buenos Aires, Argentina

[13] Hosp Univ Virgen Rocio, Med Oncol Serv, Seville, Spain

[14] Tecnol Monterrey, Hosp Zambrano Hell TecSalud, Breast Canc Ctr, Dept Med Oncol, Monterrey, Nuevo Leon, Mexico

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2024年 / 130卷 / 02期

关键词：

adjuvant chemotherapy; adjuvant drug therapy; biomarkers; breast neoplasms; clinical decision support systems; gene expression; prognosis; 21-GENE RECURRENCE SCORE; LATE DISTANT RECURRENCE; ESTROGEN-RECEPTOR; TREATMENT DECISIONS; ENDOCRINE THERAPY; 70-GENE SIGNATURE; ONCOTYPE DX; POSTMENOPAUSAL PATIENTS; RISK STRATIFICATION; IDENTIFY PATIENTS;

D O I：

10.1002/jso.27692

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gene expression assays (GEAs) can guide treatment for early-stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA. This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index (R), EndoPredict (R), MammaPrint (R), Oncotype DX (R), and Prosigna (R)). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit.

引用

页码：166 / 187

页数：22

共 139 条

[1] Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial [J].

Aalders, K. C. ;

Kuijer, A. ;

Straver, M. E. ;

Slaets, L. ;

Litiere, S. ;

Viale, G. ;

van't Veer, J. ;

Glas, A. M. ;

Delorenzi, M. ;

van Dalen, T. ;

Tryfonidis, K. ;

Piccart, M. J. ;

Cardoso, F. ;

Rutgers, E. J. .

EUROPEAN JOURNAL OF CANCER, 2017, 79 :98-105

[2]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[3] The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study [J].

Abel, Mary Kathryn ;

Shui, Amy M. ;

Melisko, Michelle ;

Chien, A. Jo ;

Yoshida, Emi J. ;

Lancaster, Elizabeth M. ;

Veer, Laura Van T. ;

Esserman, Laura J. ;

Mukhtar, Rita A. .

NPJ BREAST CANCER, 2021, 7 (01)

[4] Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial [J].

Albain, Kathy S. ;

Gray, Robert J. ;

Makower, Della F. ;

Faghih, Amir ;

Hayes, Daniel F. ;

Geyer, Charles E., Jr. ;

Dees, Elizabeth C. ;

Goetz, Matthew P. ;

Olson, John A., Jr. ;

Lively, Tracy ;

Badve, Sunil S. ;

Saphner, Thomas J. ;

Wagner, Lynne, I ;

Whelan, Timothy J. ;

Ellis, Matthew J. ;

Wood, William C. ;

Keane, Maccon M. ;

Gomez, Henry L. ;

Reddy, Pavan S. ;

Goggins, Timothy F. ;

Mayer, Ingrid A. ;

Brufsky, Adam M. ;

Toppmeyer, Deborah L. ;

Kaklamani, Virginia G. ;

Berenberg, Jeffrey L. ;

Abrams, Jeffrey ;

Sledge, George W., Jr. ;

Sparano, Joseph A. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (04) :390-399

[5] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Shak, Steven ;

Hortobagyi, Gabriel N. ;

Livingston, Robert B. ;

Yeh, I-Tien ;

Ravdin, Peter ;

Bugarini, Roberto ;

Boehner, Frederick L. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Winer, Eric P. ;

Hudis, Clifford ;

Ingle, James N. ;

Perez, Edith A. ;

Pritchard, Kathleen I. ;

Shepherd, Lois ;

Gralow, Julie R. ;

Yoshizawa, Carl ;

Allred, D. Craig ;

Osborne, C. Kent ;

Hayes, Daniel F. .

LANCET ONCOLOGY, 2010, 11 (01) :55-65

[6] Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2enegative early-stage breast cancer [J].

Albanell, Joan ;

Svedman, Christer ;

Gligorov, Joseph ;

Holt, Simon D. H. ;

Bertelli, Gianfilippo ;

Blohmer, Jens-Uwe ;

Rouzier, Roman ;

Lluch, Ana ;

Eiermann, Wolfgang .

EUROPEAN JOURNAL OF CANCER, 2016, 66 :104-113

[7] Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) [J].

不详 .

LANCET ONCOLOGY, 2007, 8 (12) :1079-1087

[8] Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis [J].

Augustovski, Federico ;

Soto, Natalie ;

Caporale, Joaquin ;

Gonzalez, Lucas ;

Gibbons, Luz ;

Ciapponi, Agustin .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (03) :611-625

[9] Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial [J].

Bartlett, J. M. S. ;

Sgroi, D. C. ;

Treuner, K. ;

Zhang, Y. ;

Ahmed, I ;

Piper, T. ;

Salunga, R. ;

Brachtel, E. F. ;

Pirrie, S. J. ;

Schnabel, C. A. ;

Rea, D. W. .

ANNALS OF ONCOLOGY, 2019, 30 (11) :1776-1783

[10] Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study [J].

Bartlett, John M. S. ;

Sgroi, Dennis C. ;

Treuner, Kai ;

Zhang, Yi ;

Piper, Tammy ;

Salunga, Ranelle C. ;

Ahmed, Ikhlaaq ;

Doos, Lucy ;

Thornber, Sarah ;

Taylor, Karen J. ;

Brachtel, Elena F. ;

Pirrie, Sarah J. ;

Schnabel, Catherine A. ;

Rea, Daniel W. .

CLINICAL CANCER RESEARCH, 2022, 28 (09) :1871-1880

← 1 2 3 4 5 6 7 8 9 10 →